Good set of FY20 results, with the momentum continued to be driven by the Americas, PetCare and Nestle Health Science. The FY21 and mid-term outlook is satisfying, roughly in line with the current consensus expectations.
18 Feb 2021
Affirmed, once again, its robustness during the year
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Affirmed, once again, its robustness during the year
Good set of FY20 results, with the momentum continued to be driven by the Americas, PetCare and Nestle Health Science. The FY21 and mid-term outlook is satisfying, roughly in line with the current consensus expectations.